We're unable to sign you in at this time. Please try again in a few minutes.
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Article |

Chloramphenicol-lnduced Bone Marrow Suppression

JAMA. 1970;213(7):1183-1184. doi:10.1001/jama.1970.03170330063011.
Text Size: A A A
Published online


Chloramphenicol produces two types of toxic effect in bone marrow: The first, a common, dose-related, reversible lesion occurs concurrently with chloramphenicol therapy and is characterized by a normally cellular marrow, maturation arrest, vacuolization in erythroid and myeloid cells, reticulocytopenia, and ferrokinetic changes indicative of suppressed erythropoiesis.1 The second is a rare, but devastating complication characterized by a late clinical onset (three to six weeks after last drug dose), lack of dose-effect relationship, bone marrow hypoplasia or aplasia, pancytopenia, and usually a fatal outcome, from hemorrhage or infection. There is no apparent relationship between these two types of toxic effect.

A great deal of progress has been made recently in elucidating the mechanism of reversible bone marrow suppression from chloramphenicol. The clinical and hematologic features of this lesion strongly suggest a direct metabolic effect of the drug on bone marrow cells. Although the mammalian cell has generally been found resistant


Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?




Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.


Some tools below are only available to our subscribers or users with an online account.

0 Citations

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

Related Content

Customize your page view by dragging & repositioning the boxes below.